产品编号 | 产品名称 | 产品包装 | 产品价格 |
SM1088-10mM | 五味子酯甲(98%, HPLC) | 10mM×0.2ml | 86.00元 |
SM1088-25mg | 五味子酯甲(98%, HPLC) | 25mg | 150.00元 |
SM1088-100mg | 五味子酯甲(98%, HPLC) | 100mg | 510.00元 |
中文名 | 五味子酯甲 |
英文名 | Schisantherin A |
中文别名 | - |
英文别名 | Gomisin C; Schisantherin A; Wuweizi ester A |
来源 | 华中五味子Schisandra sphenanthera Rehd. et Wils. |
化合物类型 | 苯丙素类(Phenylpropanoids)>木脂素>联苯环辛烯类 |
化学式 | C30H32O9 |
分子量 | 536.57 |
CAS号 | 58546-56-8 |
纯度 | 98%, HPLC |
溶剂/溶解度 |
DMSO: ≥ 100 mg/ml (186.37 mM); Water: < 0.1 mg/ml (insoluble) |
溶液配制 | 10mg加入1.86ml DMSO,或者每5.37mg加入1ml DMSO,配制成10mM溶液。 |
产品描述 | Schisantherin A is a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation. | ||||
信号通路 | - | ||||
靶点 | IκBα | TNF-α | IL-6 | NO | PGE2 |
IC50 | - | 2.5 or 25 mg/l | 2.5 or 25 mg/l | - | - |
体外研究 | The concentrations of TNF-α and IL-6 in the supernatant of cells pretreated with 2.5 or 25 mg/L of Schisantherin A are significantly decreased compared to the LPS control group (p<0.05, p<0.01). The potential cytotoxicity of Schisantherin A is evaluated by the MTT assay after incubating cells for 24 h in the absence or presence of LPS, result shows cell viabilities are not affected by the cytokines at concentrations used (0.5, 2.5, 25 mg/L). RAW 264.7 murine macrophage cells are pre-incubated with Schisantherin A for 1 h and then stimulated with 1 mg/L LPS for 12 h. Both LPS and samples are untreated in control group. After the cell culture media are collected, nitrite and PGE2 levels are determined, and Schisantherin A is found to reduce NO and PGE2 production in a dose-dependent manner. | ||||
体内研究 | Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to possess varied beneficial pharmacological effects. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Pretreatment with Schisantherin A markedly ameliorates LPS-induced histopathologic changes and decreases the levels of TNF-α, IL-6 and IL-1β in the BALF. In addition, the phosphorylation of NF-κB p65, IκB-α, JNK, ERK and p38 induced by LPS are suppressed by Schisantherin A. The lung wet/dry weight ratio is evaluated at 7 h after the intranasal instillation of LPS. The results show that there are no differences between control group and Schisantherin A (40 mg/kg) group (p>0.05). LPS causes a significant increase in lung wet/dry weight ratio (p<0.01) compared with the control group. Schisantherin A dose-dependently decreases the lung wet/dry weight ratio (p<0.05) compared to those in the LPS group. | ||||
临床实验 | N/A |
1.Ci X, et al. Inflammation. 2010,33(2):126-36.
2.Zhou E, et al. Int Immunopharmacol. 2014,22(1):133-40.
包装清单:产品编号 | 产品名称 | 包装 |
SM1088-10mM | 五味子酯甲(98%, HPLC) | 10mM×0.2ml |
SM1088-25mg | 五味子酯甲(98%, HPLC) | 25mg |
SM1088-100mg | 五味子酯甲(98%, HPLC) | 100mg |
- | 说明书 | 1份 |
-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。